|
 |
Gallium NitrateThis page contains recent news articles, when available, and an overview of Gallium Nitrate but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the US for PharmaLive.com (press release), Genta Announces Initial Clinical Trial Results for G4544, a Novel ... - 02 Jun 2008 The leading drug in Genta’s Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the US for CNNMoney.com (press release) Comtech PST Receives $2 Million Order for High Power Amplifiers - May 29, 2008 According to the company, these power amplifiers, which employ Gallium Nitrate transistor technology, offer improved efficiencies over wider bandwidths, RedOrbit, Comtech Telecommunications Corp. (CMTL) Awarded $2.0 Million of ... - May 28, 2008 These power amplifiers, which employ Gallium Nitrate (GaN) transistor technology, offer improved efficiencies over wider bandwidths, mandated by today's StreetInsider.com (subscription), Genasense(R) Chemotherapy Program Yields High Response Rate in ... - May 30, 2008 The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the US for Earthtimes (press release), OTCPicks.com Stocks to Watch for Friday, May 30th ERUC, GNTA - May 29, 2008 The leading drug in Genta's Small Molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the US for TransWorldNews (press release), Genta Incorporated Announces First Quarter 2008 Financial Results ... - May 8, 2008 The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the US for Genetic Engineering News (press release), Genta Announces Pending Transfer of its Common Stock to the Over ... - May 6, 2008 The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the US for SunHerald.com, Genta Receives Key Patent Related to Oral Gallium Compound G4544 - Apr 14, 2008 The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the US for CNNMoney.com (press release) Market Review: Progressive Market Review for Genta Incorporated - Mar 7, 2008 The leading drug in Genta's Small Molecule program is Ganite (gallium nitrate injection), which the Company is exclusively marketing in the US for treatment Trading Markets (press release), Genta Announces Licensing Agreement for Worldwide Development and ... - Mar 7, 2008 The leading drug in Genta's Small Molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the US for Lifescience-online, CFO to retire, says Genta - Feb 25, 2008 ...including Genasense (oblimersen sodium) injection, Ganite (gallium nitrate injection), and G4544, a new oral drug for accelerated bone loss. Pharmaceutical Business Review Genta Incorporated to Present at the BIO CEO & Investor Conference - Feb 5, 2008 The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the US for FOXBusiness Genta Receives Notice of Non-Compliance with Listing Requirement ... - Nov 16, 2007 The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the US for CNNMoney.com Genta bone diseases drug meets Phase I trial goals - Nov 16, 2007 ...technology developed by Emisphere Technologies that enables oral absorption of the active ingredient contained in Ganite (gallium nitrate injection). Trading Markets (press release), Genta Incorporated Announces Third Quarter 2007 Financial Results - Nov 7, 2007 The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the US for CNNMoney.com Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug ... - Nov 15, 2007 In investigational studies, high doses of gallium nitrate demonstrated consistent antitumor activity in patients with non-Hodgkin's lymphoma. PR Newswire (press release), Genta Initiates First Clinical Trial with New Oral Drug (G4544) to ... - Sep 17, 2007 G4544 is a new tablet formulation that enables oral absorption of the active ingredient contained in Ganite(R) (gallium nitrate injection), a drug that is CNNMoney.com Genta to Present at Bio Investor Forum 2007 Conference - Oct 4, 2007 The leading drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the US for CNNMoney.com Genta Reveals Initiates Bone Disorder Drug Dosing - Update [GNTA] - Sep 17, 2007 ...active ingredient contained in Ganite or gallium nitrate injection indicated in the treatment of cancer-related hypercalcemia, resistant to hydration. RTT News, ROTH 2007 New York Conference Presenter Profiles - Sep 4, 2007 The leading small molecule, Ganite(R) (gallium nitrate injection), is approved for marketing in the US for the treatment of cancer related hypercalcemia TMC Net, Genta Incorporated to Present at the ROTH Capital Partners New ... - Aug 28, 2007 The leading drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the US for CNNMoney.com Genta and Emisphere Technologies File IND with FDA for Oral Drug ... - Aug 1, 2007 CNNMoney.comIn investigational studies, high doses of gallium nitrate demonstrated consistent antitumor activity in patients with non- Hodgkin's lymphoma. Genta Announces Webcast of 2007 Annual Shareholders Meeting - 03 Jul 2007 CNNMoney.comThe leading drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the US for Genta To Request Review Of FDA Action For Genasense(R) NDA In ... - Jun 19, 2007 Medical News Today (press release),The leading drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the US for Market Report -- In Play (GNTA) - Jun 4, 2007 MSN MoneyPreviously published studies have indicated that high doses of gallium nitrate used alone or in combination with chemotherapy showed preliminary evidence of Genta Incorporated to Present Multiple Abstracts at the Annual ... - 25 May 2007 Earthtimes.orgThe lead drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the US for treatment Genta Announces New Phase 3 Trial of Genasense(R) in Patients with ... - Apr 18, 2007 PR Newswire (press release),The leading drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the US for Genta Restructures Operations to Focus on Future Initiatives - 18 Jan 2007 Drug Newswire (press release),The leading drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the US for Novel gallium compound offers treatment for lymphoma patients with ... - Dec 11, 2006 SpiritIndia,Although the cellular basis for tumor cell resistance to gallium nitrate is not well understood, gallium maltolate appears to be a unique gallium Cancer-fighting agent heads for clinical trials - Dec 7, 2006 WTN News,Clinical trials will begin in the near future to see if the compound, Titan Pharmaceutical's gallium maltolate, is a viable alternative to gallium nitrate Genta Restructures Operations to Focus on Future Initiatives - Dec 20, 2006 Drug Newswire (press release),The leading drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the US for Genta Clinical Programs Featured in Presentations at Annual ... - Dec 4, 2006 PR Newswire (press release),The leading drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the company is exclusively marketing in the US for Genta Clinical Programs Featured in Presentations at Annual ... - Dec 4, 2006 Yahoo! News (press release)The leading drug in Genta's small molecule program is Ganite® (gallium nitrate injection), which the company is exclusively marketing in the US for Genta Initiates Pilot Clinical Trial of Genasense® Plus Abraxane ... - Nov 30, 2006 PipelineReview.com (press release),The leading drug in Genta's small molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the US for : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |